Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031941 · ClinicalTrials.gov registry record · Phase 1
CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
A Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00031941 is a Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC).
The verdict
NCT00031941, a Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to previous therapy.
Interventions
- DRUG lenalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031941
The ClinicalTrials.gov registry entry for NCT00031941 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lenalidomide is the first listed.
NCT00031941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00031941 about?
NCT00031941 is a clinical study titled "CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy". RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to previous therapy.
What is the current status of trial NCT00031941?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-04. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00031941?
The interventions under investigation include: lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00031941?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.